ADMA Biologics’ (ADMA) Buy (B-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their buy (b-) rating on shares of ADMA Biologics (NASDAQ:ADMA) in a research note issued to investors on Wednesday,Weiss Ratings reports.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $14.54 on Wednesday. The company has a current ratio of 5.33, a quick ratio of 2.78 and a debt-to-equity ratio of 0.21. The firm has a 50-day moving average price of $16.34 and a two-hundred day moving average price of $18.56. ADMA Biologics has a twelve month low of $13.50 and a twelve month high of $25.67. The company has a market capitalization of $3.47 billion, a P/E ratio of 16.91 and a beta of 0.47.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period last year, the firm posted $0.13 EPS. As a group, research analysts expect that ADMA Biologics will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ADMA Biologics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its holdings in shares of ADMA Biologics by 13.9% during the first quarter. Invesco Ltd. now owns 12,866,904 shares of the biotechnology company’s stock worth $255,279,000 after buying an additional 1,570,649 shares in the last quarter. State Street Corp grew its holdings in shares of ADMA Biologics by 5.6% during the second quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after buying an additional 637,727 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of ADMA Biologics by 4.3% during the second quarter. Geode Capital Management LLC now owns 5,913,121 shares of the biotechnology company’s stock worth $107,691,000 after buying an additional 245,309 shares in the last quarter. Nuveen LLC acquired a new stake in shares of ADMA Biologics in the first quarter worth approximately $93,543,000. Finally, American Century Companies Inc. boosted its position in shares of ADMA Biologics by 8.4% in the second quarter. American Century Companies Inc. now owns 4,610,989 shares of the biotechnology company’s stock worth $83,966,000 after acquiring an additional 358,627 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.